Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Hopes To Make A Success Story of CETP Inhibitors And Obesity Drugs

Executive Summary

Merck is hoping to find success where other firms have failed: its late stage pipeline includes two programs in drug classes where the lead candidates from other companies have not managed to gain approval

You may also be interested in...



“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO

Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say

“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO

Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say

Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo

Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug

Related Content

UsernamePublicRestriction

Register

PS049124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel